Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction
Jazyk angličtina Země Nizozemsko Médium print
Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, pozorovací studie, práce podpořená grantem
PubMed
26340851
DOI
10.1007/s11239-015-1274-7
PII: 10.1007/s11239-015-1274-7
Knihovny.cz E-zdroje
- Klíčová slova
- Cardiac arrest, Clopidogrel, Hypothermia, Myocardial infarction, Prasugrel, Ticagrelor,
- MeSH
- adenosin aplikace a dávkování analogy a deriváty MeSH
- infarkt myokardu komplikace terapie MeSH
- klopidogrel MeSH
- lidé středního věku MeSH
- lidé MeSH
- prasugrel hydrochlorid aplikace a dávkování MeSH
- prospektivní studie MeSH
- purinergní receptory P2Y - agonisté aplikace a dávkování MeSH
- senioři MeSH
- srdeční zástava etiologie terapie MeSH
- terapeutická hypotermie metody MeSH
- ticagrelor MeSH
- tiklopidin aplikace a dávkování analogy a deriváty MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- adenosin MeSH
- klopidogrel MeSH
- prasugrel hydrochlorid MeSH
- purinergní receptory P2Y - agonisté MeSH
- ticagrelor MeSH
- tiklopidin MeSH
Survivors after cardiac arrest (CA) due to AMI undergo PCI and then receive dual antiplatelet therapy. Mild therapeutic hypothermia (MTH) is recommended for unconscious patients after CA to improve neurological outcomes. MTH can attenuate the effectiveness of P2Y12 inhibitors by reducing gastrointestinal absorption and metabolic activation. The combined effect of these conditions on the efficacy of P2Y12 inhibitors is unknown. We compared the antiplatelet efficacies of new P2Y12 inhibitors in AMI patients after CA treated with MTH. Forty patients after CA for AMI treated with MTH and received one P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) were enrolled in a prospective observational single-center study. Platelet inhibition was measured by VASP (PRI) on days 1, 2, and 3 after drug administration. In-hospital clinical data and 1-year survival data were obtained. The proportion of patients with ineffective platelet inhibition (PRI > 50 %, high on-treatment platelet reactivity) for clopidogrel, prasugrel, and ticagrelor was 77 vs. 19 vs. 1 % on day 1; 77 vs. 17 vs. 0 % on day 2; and 85 vs. 6 vs. 0 % on day 3 (P < 0.001). The platelet inhibition was significantly worse in clopidogrel group than in prasugrel or ticagrelor group. Prasugrel and ticagrelor are very effective for platelet inhibition in patients treated with MTH after CA due to AMI, but clopidogrel is not. Using prasugrel or ticagrelor seems to be a more suitable option in this high-risk group of acute patients.
Zobrazit více v PubMed
Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1607-16 PubMed
Resuscitation. 2010 Dec;81(12):1627-31 PubMed
Eur J Clin Pharmacol. 2013 Mar;69(3):309-17 PubMed
Thromb Res. 2009 Feb;123(4):597-603 PubMed
Crit Care Med. 2007 Sep;35(9):2196-204 PubMed
Circulation. 2011 Jun 14;123(23):2736-47 PubMed
Resuscitation. 2014 May;85(5):649-56 PubMed
Am Heart J. 2007 Jan;153(1):66.e9-16 PubMed
Resuscitation. 2010 Oct;81 Suppl 1:e1-25 PubMed
J Am Coll Cardiol. 2005 Nov 15;46(10):1820-6 PubMed
Platelets. 2010;21(1):44-8 PubMed
Eur Heart J. 2012 Oct;33(20):2569-619 PubMed
J Am Coll Cardiol. 2005 Apr 19;45(8):1157-64 PubMed
Intensive Care Med. 2008 Mar;34(3):454-60 PubMed
J Am Coll Cardiol. 2010 Sep 14;56(12):919-33 PubMed
Drug Metab Dispos. 2011 Dec;39(12):2209-18 PubMed
Lancet. 2010 Jan 23;375(9711):283-93 PubMed
Catheter Cardiovasc Interv. 2010 Feb 1;75(2):158-66 PubMed
Am J Cardiovasc Drugs. 2014 Aug;14(4):313-8 PubMed
N Engl J Med. 2013 Dec 5;369(23):2197-206 PubMed
J Thromb Haemost. 2006 Mar;4(3):542-9 PubMed
Crit Care Med. 2009 Jul;37(7 Suppl):S186-202 PubMed
Thromb J. 2009 Feb 23;7:2 PubMed
